Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis

References

• Meyer KC. Idiopathic pulmonary fibrosis: a historical perspective. In: Meyer KC, Nathan SD, Eds. Idiopathic pulmonary fibrosis: a comprehensive clinical guide. Humana: Springer; 2014. p. 1–8.
   Google Scholar
• Collard HR, King TE Jr. Diffuse lung disease: classification and evaluation. In: Baughman RP, Roland M, Du Bois RM, Eds. Diffuse lung disease: a practical approach. Second ed. New York: Springer; 2012. p. 85–100.
   Google Scholar
• Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013 Sep 15;188(6):733–748.
   PubMed Web of Science ®Google Scholar
• King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011 Dec 3;378(9807):1949–1961.
   PubMed Web of Science ®Google Scholar
• Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006 Oct 1;174(7):810–816.
   PubMed Web of Science ®Google Scholar
• Olson AL, Swigris JJ, Lezotte DC, et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med. 2007 Aug 1;176(3):277–284.
   PubMed Web of Science ®Google Scholar
• Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med. 2014 Jul;2(7):566–572.
   PubMed Web of Science ®Google Scholar
• Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Feb 15;183(4):431–440.
   PubMed Web of Science ®Google Scholar
• Raghu G, Collard HR, Egan JJ, et al. ATS/ERS/JRS/ALAT committee on idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.
   PubMed Web of Science ®Google Scholar
• Katzenstein AL, Zisman DA, Litzky LA, et al. Usual interstitial pneumonia: histologic study of biopsy and explant specimens. Am J Surg Pathol. 2002 Dec;26(12):1567–1577.
   PubMed Web of Science ®Google Scholar
• Todd NW, Galvin JR, Sachdeva A, et al. Microscopic organizing pneumonia and cellular non-specific interstitial pneumonia are widespread in macroscopically normal-appearing lung tissue in idiopathic pulmonary fibrosis. J Heart Lung Transplant. 2016 Nov;35(11):1367–1370.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Travis WD, Colby TV, et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med. 2001 Nov 1;164(9):1722–1727.
   PubMed Web of Science ®Google Scholar
• Larsen BT, Smith ML, Elicker BM, et al. Diagnostic approach to advanced fibrotic interstitial lung disease: bringing together clinical, radiologic, and histologic clues. Arch Pathol Lab Med. 2016 Sep 15. doi: 10.5858/arpa.2016-0299-SA. [Epub ahead of print].
   Google Scholar
• Mathai SK, Yang IV, Schwarz MI, et al. Incorporating genetics into the identification and treatment of idiopathic pulmonary fibrosis. BMC Med. 2015 Sep 24;13(1):191.
   PubMed Web of Science ®Google Scholar
• Tzouvelekis A, Kaminski N. Epigenetics in idiopathic pulmonary fibrosis. Biochem Cell Biol. 2015 Apr;93(2):159–170.
   PubMed Web of Science ®Google Scholar
• Raghu G, Rochwerg B, Zhang Y, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015 Jul 15;192(2):e3–19.
   PubMed Web of Science ®Google Scholar
• King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083–2092.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–2082.
   PubMed Web of Science ®Google Scholar
• Nathan SD, Shlobin OA, Weir N, et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest. 2011;140:221–229.
   PubMed Web of Science ®Google Scholar
• Whitsett JA, Wert SE, Weaver TE. Diseases of pulmonary surfactant homeostasis. Annu Rev Pathol. 2015;10:371–393.
   PubMed Web of Science ®Google Scholar
• Newton CA, Batra K, Torrealba J, et al. Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive. Eur Respir J. 2016 Dec;48(6):1710–1720.
   PubMed Web of Science ®Google Scholar
• Garcia CK. Idiopathic pulmonary fibrosis: update on genetic discoveries. Proc Am Thorac Soc. 2011 May;8(2):158–162.
   PubMedGoogle Scholar
• Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011 Apr 21;364(16):1503–1512.
   PubMed Web of Science ®Google Scholar
• Fingerlin TE, Murphy E, Zhang W, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet. 2013 Jun;45(6):613–620.
   PubMed Web of Science ®Google Scholar
• Hunninghake GM, Hatabu H, Okajima Y, et al. MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med. 2013 Jun 6;368(23):2192–2200.
   PubMed Web of Science ®Google Scholar
• Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. Jama. 2013 Jun 5;309(21):2232–2239.
   PubMed Web of Science ®Google Scholar
• Noth I, Zhang Y, Ma SF, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med. 2013 Jun;1(4):309–317.
   PubMed Web of Science ®Google Scholar
• O’Dwyer DN, Armstrong ME, Trujillo G, et al. The Toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2013 Dec 15;188(12):1442–1450.
   PubMed Web of Science ®Google Scholar
• Herazo-Maya JD, Kaminski N. Evolving genomics of pulmonary fibrosis. In: Meyer KC, Nathan SD, Eds. Idiopathic pulmonary fibrosis. New York: Humana Press, Springer; 2014. p. 379–402.
   Google Scholar
• Yang IV. Epigenomics of idiopathic pulmonary fibrosis. Epigenomics. 2012 Apr;4(2):195–203.
   PubMed Web of Science ®Google Scholar
• Sanders YY, Pardo A, Selman M, et al. Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2008 Nov;39(5):610–618.
   PubMed Web of Science ®Google Scholar
• Cisneros J, Hagood J, Checa M, et al. Hypermethylation-mediated silencing of p14(ARF) in fibroblasts from idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2012 Aug 15;303(4):L295–303.
   PubMed Web of Science ®Google Scholar
• Huang SK, Fisher AS, Scruggs AM, et al. Hypermethylation of PTGER2 confers prostaglandin E2 resistance in fibrotic fibroblasts from humans and mice. Am J Pathol. 2010 Nov;177(5):2245–2255.
   PubMed Web of Science ®Google Scholar
• Sanders YY, Ambalavanan N, Halloran B, et al. Altered DNA methylation profile in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012 Sep 15;186(6):525–535.
   PubMed Web of Science ®Google Scholar
• Coward WR, Watts K, Feghali-Bostwick CA, et al. Repression of IP-10 by interactions between histone deacetylation and hypermethylation in idiopathic pulmonary fibrosis. Mol Cell Biol. 2010 Jun;30(12):2874–2886.
   PubMed Web of Science ®Google Scholar
• Huang SK, Scruggs AM, Donaghy J, et al. Histone modifications are responsible for decreased Fas expression and apoptosis resistance in fibrotic lung fibroblasts. Cell Death Dis. 2013 May;2(4):e621.
   Web of Science ®Google Scholar
• Milosevic J, Pandit K, Magister M, et al. Profibrotic role of miR-154 in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2012 Dec;47(6):879–887.
   PubMed Web of Science ®Google Scholar
• Pandit KV, Corcoran D, Yousef H, et al. Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2010 Jul 15;182(2):220–229.
   PubMed Web of Science ®Google Scholar
• Cui H, Ge J, Xie N, et al. miR-34a inhibits lung fibrosis by inducing lung fibroblast senescence. Am J Respir Cell Mol Biol. 2017 Feb;56(2):168–178.
   PubMed Web of Science ®Google Scholar
• Cui H, Ge J, Xie N, et al. miR-34a promotes fibrosis in aged lungs by inducing alveolar epithelial dysfunctions. Am J Physiol Lung Cell Mol Physiol. 2016 Dec 15; ajplung.00335: 2016. Epub ahead of print. DOI:10.1152/ajplung.00335.2016
   Google Scholar
• Tourin O, Swigris JJ, Olson AL. Idiopathic pulmonary fibrosis: the epidemiology and natural history of disease. In: Meyer KC, Nathan SD, Eds. Idiopathic pulmonary fibrosis. New York: Humana Press, Springer; 2014. p. 9–34.
   Google Scholar
• Caminati A, Madotto F, Cesana G, et al. Epidemiological studies in idiopathic pulmonary fibrosis: pitfalls in methodologies and data interpretation. Eur Respir Rev. 2015 Sep;24(137):436–444.
   PubMedGoogle Scholar
• Raghu G, Chen SY, Hou Q, et al. Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18-64 years old. Eur Respir J. 2016 Jul;48(1):179–186.
   PubMed Web of Science ®Google Scholar
• Von Plessen C, Grinde O, Gulsvik A. Incidence and prevalence of cryptogenic fibrosing alveolitis in a Norwegian community. Respir Med. 2003 Apr;97(4):428–435.
   PubMed Web of Science ®Google Scholar
• Raghu G, Meyer KC. Silent gastro-oesophageal reflux and microaspiration in IPF: mounting evidence for anti-reflux therapy? Eur Respir J. 2012 Feb;39(2):242–245.
   PubMed Web of Science ®Google Scholar
• Nathan SD. Idiopathic pulmonary fibrosis phenotypes. In: Meyer KC, Nathan SD, Eds. Idiopathic pulmonary fibrosis. New York: Humana Press, Springer; 2014. p. 221–238.
   Google Scholar
• Du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Aug 15;184(4):459–466.
   PubMed Web of Science ®Google Scholar
• Milne KM, Kwan JM, Guler S, et al. Frailty is common and strongly associated with dyspnoea severity in fibrotic interstitial lung disease. Respirology. 2016 Nov 9. Epub ahead of print. DOI:10.1111/resp.12944
   PubMed Web of Science ®Google Scholar
• Hook JL, Arcasoy SM, Zemmel D, et al. Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis. Eur Respir J. 2012 Feb;39(2):359–365.
   PubMed Web of Science ®Google Scholar
• Nathan SD, Meyer KC. IPF clinical trial design and endpoints. Curr Opin Pulm Med. 2014 Sep;20(5):463–471.
   PubMed Web of Science ®Google Scholar
• Raghu G, Collard HR, Anstrom KJ, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2012 May 15;185(10):1044–1048.
   PubMed Web of Science ®Google Scholar
• Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006 Mar;129(3):746–752.
   PubMed Web of Science ®Google Scholar
• Nathan SD, Basavaraj A, Reichner C, et al. Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. Respir Med. 2010 Jul;104(7):1035–1041.
   PubMed Web of Science ®Google Scholar
• Lee JS, Ryu JH, Elicker BM, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Dec 15;184(12):1390–1394.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Thwaite EL, Kazerooni EA, et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax. 2003 Feb;58(2):143–148.
   PubMed Web of Science ®Google Scholar
• Lynch DA, Godwin JD, Safrin S, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med. 2005 Aug 15;172(4):488–493.
   PubMed Web of Science ®Google Scholar
• Oda K, Ishimoto H, Yatera K, et al. High-resolution CT scoring system-based grading scale predicts the clinical outcomes in patients with idiopathic pulmonary fibrosis. Respir Res. 2014 Jan;30(15):10.
   Web of Science ®Google Scholar
• Ley B, Elicker BM, Hartman TE, et al. Idiopathic pulmonary fibrosis: CT and risk of death. Radiology. 2014 Nov;273(2):570–579.
   PubMed Web of Science ®Google Scholar
• Du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med. 2011 Dec 15;184(12):1382–1389.
   PubMed Web of Science ®Google Scholar
• Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J. 2010 Apr;35(4):830–836.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Andrei AC, Murray S, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med. 2006 Oct 1;174(7):803–809.
   PubMed Web of Science ®Google Scholar
• Du Bois RM, Albera C, Bradford WZ, et al. 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2014 May;43(5):1421–1429.
   PubMed Web of Science ®Google Scholar
• Du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med. 2011 May 1;183(9):1231–1237.
   PubMed Web of Science ®Google Scholar
• Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003 Nov 1;168(9):1084–1090.
   PubMed Web of Science ®Google Scholar
• King TE Jr, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med. 2001 Oct 1;164(7):1171–1181.
   PubMed Web of Science ®Google Scholar
• Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012 May 15;156(10):684–691.
   PubMed Web of Science ®Google Scholar
• Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003 Apr 1;167(7):962–969.
   PubMed Web of Science ®Google Scholar
• Ley B, Bradford WZ, Weycker D, et al. Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis. Eur Respir J. 2015 May;45(5):1374–1381.
   PubMed Web of Science ®Google Scholar
• Ryerson CJ, Vittinghoff E, Ley B, et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2014 Apr;145(4):723–728.
   PubMed Web of Science ®Google Scholar
• Ley B, Bradford WZ, Vittinghoff E, et al. Predictors of mortality poorly predict common measures of disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2016 Sep 15;194(6):711–718.
   PubMed Web of Science ®Google Scholar
• Walsh SL, Wells AU, Sverzellati N, et al. An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. Lancet Respir Med. 2014 Feb;2(2):123–130.
   PubMed Web of Science ®Google Scholar
• Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008 Jun 1;177(11):1248–1254.
   PubMed Web of Science ®Google Scholar
• Walsh SL, Sverzellati N, Devaraj A, et al. Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants. Thorax. 2014 Mar;69(3):216–222.
   PubMed Web of Science ®Google Scholar
• Walsh SL, Sverzellati N, Devaraj A, et al. Chronic hypersensitivity pneumonitis: high resolution computed tomography patterns and pulmonary function indices as prognostic determinants. Eur Radiol. 2012 Aug;22(8):1672–1679.
   PubMed Web of Science ®Google Scholar
• Urisman A, Jones KD. Pulmonary pathology in connective tissue disease. Semin Respir Crit Care Med. 2014 Apr;35(2):201–212.
   PubMed Web of Science ®Google Scholar
• Lee JS, Fischer A. Current and emerging treatment options for interstitial lung disease in patients with rheumatic disease. Expert Rev Clin Immunol. 2016;12(5):509–520.
   PubMed Web of Science ®Google Scholar
• Meyer KC, Bierach J. Immunosuppressive therapy for autoimmune lung diseases. Immunol Allergy Clin North Am. 2012 Nov;32(4):633–669.
   PubMed Web of Science ®Google Scholar
• Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012;366(21):1968–1977.
   PubMed Web of Science ®Google Scholar
• Duncan S. The role of adaptive immunity in idiopathic pulmonary fibrosis: hiding in plain sight. In: Idiopathic pulmonary fibrosis. Meyer KC, Nathan SD, Eds, New York: Humana Press, Springer; 2014. p. 123–59.
   Google Scholar
• Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013 May;40(5):640–646.
   PubMed Web of Science ®Google Scholar
• Selman M, Rojas M, Mora AL, et al. Aging and interstitial lung diseases: unraveling an old forgotten player in the pathogenesis of lung fibrosis. Semin Respir Crit Care Med. 2010 Oct;31(5):607–617.
   PubMed Web of Science ®Google Scholar
• Selman M, Pardo A. Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. an integral model. Am J Respir Crit Care Med. 2014 May 15;189(10):1161–1172.
   PubMed Web of Science ®Google Scholar
• Sandbo N. Mechanisms of fibrosis in IPF. In: Meyer KC, Nathan SD, Eds. Idiopathic pulmonary fibrosis. New York: Humana Press, Springer; 2014. p. 161–205.
   Google Scholar
• Myers JL. Histopathology of IPF and related disorders. In: Meyer KC, Sd N, Eds. Idiopathic pulmonary fibrosis. New York: Humana Press, Springer; 2014. p. 35–54.
   Google Scholar
• Cool CD, Groshong SD, Rai PR, et al. Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum. Am J Respir Crit Care Med. 2006 Sep 15;174(6):654–658.
   PubMed Web of Science ®Google Scholar
• Liang J, Zhang Y, Xie T, et al. Hyaluronan and TLR4 promote surfactant-protein-C-positive alveolar progenitor cell renewal and prevent severe pulmonary fibrosis in mice. Nat Med. 2016 Nov;22(11):1285–1293.
   PubMed Web of Science ®Google Scholar
• Chilosi M, Poletti V, Murer B, et al. Abnormal re-epithelialization and lung remodeling in idiopathic pulmonary fibrosis: the role of deltaN-p63. Lab Invest. 2002 Oct;82(10):1335–1345.
   PubMed Web of Science ®Google Scholar
• Puglisi S, Torrisi SE, Giuliano R, et al. What we know about the pathogenesis of idiopathic pulmonary fibrosis. Semin Respir Crit Care Med. 2016 Jun;37(3):358–367.
   PubMed Web of Science ®Google Scholar
• Pardo A, Selman M. Lung fibroblasts, aging, and idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2016;13(Suppl 5):S417–21.
   PubMed Web of Science ®Google Scholar
• Selman M, López-Otín C, Pardo A. Age-driven developmental drift in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir J. 2016 Aug;48(2):538–552.
   PubMed Web of Science ®Google Scholar
• Hecker L, Logsdon NJ, Kurundkar D, et al. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci Transl Med. 2014 Apr 9;6(231):231ra47.
   PubMed Web of Science ®Google Scholar
• Selman M, Romero Y, Pardo A. Aging and IPF: what is the link? In: Meyer KC, Nathan SD, Eds. Idiopathic pulmonary fibrosis. New York: Humana Press, Springer; 2014. p. 259–279.
   Google Scholar
• Selman M, Pardo A, Kaminski N. Idiopathic pulmonary fibrosis: aberrant recapitulation of developmental programs? PLoS Med. 2008 Mar 4;5(3):e62.
   PubMed Web of Science ®Google Scholar
• Sennello JA, Misharin AV, Flozak AS, et al. Lrp5/β-catenin signaling controls lung macrophage differentiation and inhibits resolution of fibrosis. Am J Respir Cell Mol Biol. 2017 Feb;56(2):191–201.
   PubMedGoogle Scholar
• Leslie KO. Idiopathic pulmonary fibrosis may be a disease of recurrent, tractional injury to the periphery of the aging lung: a unifying hypothesis regarding etiology and pathogenesis. Arch Pathol Lab Med. 2012 Jun;136(6):591–600.
   PubMed Web of Science ®Google Scholar
• Thannickal VJ, Henke CA, Horowitz JC, et al. Matrix biology of idiopathic pulmonary fibrosis: a workshop report of the national heart, lung, and blood institute. Am J Pathol. 2014 Jun;184(6):1643–1651.
   PubMed Web of Science ®Google Scholar
• Parker MW, Rossi D, Peterson M, et al. Fibrotic extracellular matrix activates a profibrotic positive feedback loop. J Clin Invest. 2014 Apr;124(4):1622–1635.
   PubMed Web of Science ®Google Scholar
• Froese AR, Shimbori C, Bellaye PS, et al. Stretch-induced activation of transforming growth factor-β1 in pulmonary fibrosis. Am J Respir Crit Care Med. 2016 Jul 1;194(1):84–96.
   PubMed Web of Science ®Google Scholar
• Han MK, Zhou Y, Murray S, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med. 2014 Jul;2(7):548–556.
   PubMed Web of Science ®Google Scholar
• Molyneaux PL, Cox MJ, Wells AU, et al. Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis. Respir Res. 2017 Feb 1;18(1):29.
   PubMed Web of Science ®Google Scholar
• Ellson CD, Dunmore R, Hogaboam CM, et al. Danger-associated molecular patterns and danger signals in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 2014 Aug;51(2):163–168.
   PubMed Web of Science ®Google Scholar
• Wadwha A, Flaherty KR. The keys to making a confident diagnosis of IPF. In: Meyer KC, Nathan SD, Eds. Idiopathic pulmonary fibrosis. New York: Humana Press, Springer; 2014. p. 77–99.
   Google Scholar
• Meyer KC. Diagnosis and management of interstitial lung disease. Transl Respir Med. 2014 Feb;13(2):4.
   Google Scholar
• Martinez FJ, Chisholm A, Collard HR, et al. The diagnosis of idiopathic pulmonary fibrosis: current and future approaches. Lancet Respir Med. 2017 Jan;5(1):61–71.
   PubMed Web of Science ®Google Scholar
• Putman RK, Hatabu H, Araki T, et al. Association between interstitial lung abnormalities and all-cause mortality. Jama. 2016 Feb 16;315(7):672–681.
   PubMed Web of Science ®Google Scholar
• Podolanczuk AJ, Oelsner EC, Barr RG, et al. High attenuation areas on chest computed tomography in community-dwelling adults: the MESA study. Eur Respir J. 2016 Nov;48(5):1442–1452.
   PubMed Web of Science ®Google Scholar
• Araki T, Putman RK, Hatabu H, et al. Development and progression of interstitial lung abnormalities in the framingham heart study. Am J Respir Crit Care Med. 2016 Dec 15;194(12):1514–1522.
   PubMed Web of Science ®Google Scholar
• Fell CD, Martinez FJ, Liu LX, et al. Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2010 Apr 15;181(8):832–837.
   PubMed Web of Science ®Google Scholar
• Patterson KC, Shah RJ, Porteous MK, et al. Interstitial lung disease in the elderly. Chest. 2016 Nov 16;pii:S0012-3692(16)62347-4. Epub ahead of print. DOI: 10.1016/j.chest.2016.11.003
   Google Scholar
• Raghu G, Lynch D, Godwin JD, et al. Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial. Lancet Respir Med. 2014 Apr;2(4):277–284.
   PubMed Web of Science ®Google Scholar
• Raghu G, Wells AU, Nicholson AG, et al. Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria. Am J Respir Crit Care Med. 2017 Jan 1;195(1):78–85.
   PubMed Web of Science ®Google Scholar
• Morell F, Villar A, Ojanguren I, et al. Hypersensitivity pneumonitis: challenges in diagnosis and management, avoiding surgical lung biopsy. Semin Respir Crit Care Med. 2016 Jun;37(3):395–405.
   PubMed Web of Science ®Google Scholar
• Selman M, Pardo A, King TE Jr. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med. 2012 Aug 15;186(4):314–324.
   PubMed Web of Science ®Google Scholar
• Salisbury ML, Myers JL, Belloli EA, et al. Diagnosis and treatment of fibrotic hypersensitivity pneumonia. where we stand and where we need to go. Am J Respir Crit Care Med. 2016 Dec 21. Epub ahead of print. DOI:10.1164/rccm.201608-1675PP
   PubMedGoogle Scholar
• Walsh SL, Wells AU, Desai SR, et al. Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study. Lancet Respir Med. 2016 Jul;4(7):557–565.
   PubMed Web of Science ®Google Scholar
• Meyer KC, Raghu G, Baughman RP, et al. An official American thoracic society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012 May 1;185(9):1004–1014.
   PubMed Web of Science ®Google Scholar
• Ohshimo S, Bonella F, Cui A, et al. Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009 Jun 1;179(11):1043–1047.
   PubMed Web of Science ®Google Scholar
• Berbescu EA, Katzenstein AL, Snow JL, et al. Transbronchial biopsy in usual interstitial pneumonia. Chest. 2006 May;129(5):1126–1131.
   PubMed Web of Science ®Google Scholar
• Tomassetti S, Wells AU, Costabel U, et al. Bronchoscopic lung cryobiopsy increases diagnostic confidence in the multidisciplinary diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2016 Apr 1;193(7):745–752.
   PubMed Web of Science ®Google Scholar
• Ravaglia C, Bonifazi M, Wells AU, et al. Safety and diagnostic yield of transbronchial lung cryobiopsy in diffuse parenchymal lung diseases: a comparative study versus video-assisted thoracoscopic lung biopsy and a systematic review of the literature. Respiration. 2016;91(3):215–227.
   PubMed Web of Science ®Google Scholar
• Colby TV, Tomassetti S, Cavazza A, et al. Transbronchial cryobiopsy in diffuse lung disease: update for the pathologist. Arch Pathol Lab Med. 2016 Sep 2. doi: 10.5858/arpa.2016-0233-RA. [Epub ahead of print].
   Google Scholar
• Nguyen W, Meyer KC. Surgical lung biopsy for the diagnosis of interstitial lung disease: a review of the literature and recommendations for optimizing safety and efficacy. Sarcoidosis Vasc Diffuse Lung Dis. 2013 Mar;30(1):3–16.
   PubMed Web of Science ®Google Scholar
• Sakamoto K, Taniguchi H, Kondoh Y, et al. Acute exacerbation of IPF following diagnostic bronchoalveolar lavage procedures. Respir Med. 2012 Mar;106(3):436–442.
   PubMed Web of Science ®Google Scholar
• Kondoh Y, Taniguchi H, Kitaichi M, et al. Acute exacerbation of interstitial pneumonia following surgical lung biopsy. Respir Med. 2006 Oct;100(10):1753–1759.
   PubMed Web of Science ®Google Scholar
• Hutchinson JP, Fogarty AW, McKeever TM, et al. In-hospital mortality after surgical lung biopsy for interstitial lung disease in the United States. 2000 to 2011. Am J Respir Crit Care Med. 2016 May 15;193(10):1161–1167.
   PubMed Web of Science ®Google Scholar
• Kim SY, Diggans J, Pankratz D, et al. Classification of usual interstitial pneumonia in patients with interstitial lung disease: assessment of a machine learning approach using high-dimensional transcriptional data. Lancet Respir Med. 2015 Jun;3(6):473–482.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, King TE Jr, Raghu G, et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med. 2004 Oct 15;170(8):904–910.
   PubMed Web of Science ®Google Scholar
• De Andrade J, Schwarz M, Collard HR, et al. The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet): diagnostic and adjudication processes. Chest. 2015 Oct 1;148(4):1034–1042.
   PubMed Web of Science ®Google Scholar
• Tominaga J, Sakai F, Johkoh T, et al. Diagnostic certainty of idiopathic pulmonary fibrosis/usual interstitial pneumonia: the effect of the integrated clinico-radiological assessment. Eur J Radiol. 2015 Dec;84(12):2640–2645.
   PubMed Web of Science ®Google Scholar
• Cottin V, Crestani B, Valeyre D, et al. Diagnosis and management of idiopathic pulmonary fibrosis: French practical guidelines. Eur Respir Rev. 2014 Jun;23(132):193–214.
   PubMedGoogle Scholar
• Spagnolo P, Grunewald J, Du Bois RM. Genetic determinants of pulmonary fibrosis: evolving concepts. Lancet Respir Med. 2014 May;2(5):416–428.
   PubMed Web of Science ®Google Scholar
• Ley B, Brown KK, Collard HR. Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2014 Nov 1;307(9):L681–91.
   PubMed Web of Science ®Google Scholar
• Daccord C, Maher TM. Recent advances in understanding idiopathic pulmonary fibrosis. F1000Res. 2016 May 31; 5. pii:F1000 Faculty Rev-1046.
   Google Scholar
• White ES, Xia M, Murray S, et al. Plasma surfactant Protein-D, Matrix Metalloproteinase-7, and osteopontin index distinguishes idiopathic pulmonary fibrosis from other idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2016 Nov 15;194(10):1242–1251.
   PubMed Web of Science ®Google Scholar
• Raghu G, Amatto VC, Behr J, et al. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J. 2015 Oct;46(4):1113–1130.
   PubMed Web of Science ®Google Scholar
• Meyer KC, Danoff SK, Lancaster LH, et al. Management of idiopathic pulmonary fibrosis in the elderly patient: addressing key questions. Chest. 2015 Jul;148(1):242–252.
   PubMed Web of Science ®Google Scholar
• King CS, Nathan SD. Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. Lancet Respir Med. 2017 Jan;5(1):72–84.
   PubMed Web of Science ®Google Scholar
• Mejía M, Carrillo G, Rojas-Serrano J, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest. 2009 Jul;136(1):10–15.
   PubMed Web of Science ®Google Scholar
• Ryerson CJ, Hartman T, Elicker BM, et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest. 2013 Jul;144(1):234–240.
   PubMed Web of Science ®Google Scholar
• Jankowich MD, Rounds SI. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest. 2012 Jan;141(1):222–231.
   PubMed Web of Science ®Google Scholar
• Lin H, Jiang S. Combined pulmonary fibrosis and emphysema (CPFE): an entity different from emphysema or pulmonary fibrosis alone. J Thorac Dis. 2015 Apr;7(4):767–779.
   PubMed Web of Science ®Google Scholar
• Nathan SD, Basavaraj A, Reichner C, et al. Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. Respir Med. 2010 Jul;104(7):1035–1041.
   PubMed Web of Science ®Google Scholar
• Kim WY, Mok Y, Kim GW, et al. Association between idiopathic pulmonary fibrosis and coronary artery disease: a case-control study and cohort analysis. Sarcoidosis Vasc Diffuse Lung Dis. 2015 Jan 5;31(4):289–296.
   PubMed Web of Science ®Google Scholar
• Vittal R, Mickler EA, Fisher AJ, et al. Type V collagen induced tolerance suppresses collagen deposition, TGF-β and associated transcripts in pulmonary fibrosis. PLoS One. 2013 Oct 21;8(10):e76451.
   PubMed Web of Science ®Google Scholar
• Dart ML, Jankowska-Gan E, Huang G, et al. Interleukin-17-dependent autoimmunity to collagen type V in atherosclerosis. Circ Res. 2010 Oct 29;107(9):1106–1116.
   PubMed Web of Science ®Google Scholar
• Lancaster LH, Mason WR, Parnell JA, et al. Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest. 2009 Sep;136(3):772–778.
   PubMed Web of Science ®Google Scholar
• Schiza S, Mermigkis C, Margaritopoulos GA, et al. Idiopathic pulmonary fibrosis and sleep disorders: no longer strangers in the night. Eur Respir Rev. 2015 Jun;24(136):327–339.
   PubMedGoogle Scholar
• Pillai M, Olson AL, Huie TJ, et al. Obstructive sleep apnea does not promote esophageal reflux in fibrosing interstitial lung disease. Respir Med. 2012 Jul;106(7):1033–1039.
   PubMed Web of Science ®Google Scholar
• Weng T, Poth JM, Karmouty-Quintana H, et al. Hypoxia-induced deoxycytidine kinase contributes to epithelial proliferation in pulmonary fibrosis. Am J Respir Crit Care Med. 2014 Dec 15;190(12):1402–1412.
   PubMed Web of Science ®Google Scholar
• Kottmann RM, Kulkarni AA, Smolnycki KA, et al. Lactic acid is elevated in idiopathic pulmonary fibrosis and induces myofibroblast differentiation via pH-dependent activation of transforming growth factor-β. Am J Respir Crit Care Med. 2012 Oct 15;186(8):740–751.
   PubMed Web of Science ®Google Scholar
• Adegunsoye A. Balachandran J Inflammatory response mechanisms exacerbating hypoxemia in coexistent pulmonary fibrosis and sleep apnea. Mediators Inflamm. 2015;2015:510105.
   PubMed Web of Science ®Google Scholar
• Noth I, Zangan SM, Soares RV, et al. Prevalence of hiatal hernia by blinded multidetector CT in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2012 Feb;39(2):344–351.
   PubMed Web of Science ®Google Scholar
• Raghu G, Freudenberger TD, Yang S, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J. 2006 Jan;27(1):136–142.
   PubMed Web of Science ®Google Scholar
• Hoppo T, Komatsu Y, Jobe BA. Gastroesophageal reflux disease and patterns of reflux in patients with idiopathic pulmonary fibrosis using hypopharyngeal multichannel intraluminal impedance. Dis Esophagus. 2014 Aug;27(6):530–537.
   PubMed Web of Science ®Google Scholar
• Raghu G, Yang ST, Spada C, et al. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest. 2006 Mar;129(3):794–800.
   PubMed Web of Science ®Google Scholar
• Lee JS, Collard HR, Anstrom KJ, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med. 2013 Jul;1(5):369–376.
   PubMed Web of Science ®Google Scholar
• Lee JS, Song JW, Wolters PJ, et al. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J. 2012 Feb;39(2):352–358.
   PubMed Web of Science ®Google Scholar
• Savarino E, Carbone R, Marabotto E, et al. Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. Eur Respir J. 2013 Nov;42(5):1322–1331.
   PubMed Web of Science ®Google Scholar
• Hershcovici T, Jha LK, Johnson T, et al. Systematic review: the relationship between interstitial lung diseases and gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2011 Dec;34(11–12):1295–1305.
   PubMed Web of Science ®Google Scholar
• Ryu JH, Moua T, Daniels CE, et al. Idiopathic pulmonary fibrosis: evolving concepts. Mayo Clin Proc. 2014 Aug;89(8):1130–1142.
   PubMed Web of Science ®Google Scholar
• Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007 Oct 1;176(7):636–643.
   PubMed Web of Science ®Google Scholar
• Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med. 2016 Aug 1;194(3):265–275.
   PubMed Web of Science ®Google Scholar
• Ryerson CJ, Cottin V, Brown KK, et al. Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm. Eur Respir J. 2015 Aug;46(2):512–520.
   PubMed Web of Science ®Google Scholar
• Lee JS, Collard HR. Acute exacerbation of pulmonary fibrosis. In: Meyer KC, Nathan SD, Eds. Idiopathic pulmonary fibrosis. New York: Humana Press, Springer; 2014. p. 349–362.
   Google Scholar
• Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011 Feb;37(2):356–363.
   PubMed Web of Science ®Google Scholar
• Moore BB, Moore TA. Viruses in idiopathic pulmonary fibrosis. Etiology and exacerbation. Ann Am Thorac Soc. 2015 Nov;12(Suppl 2):S186–92.
   PubMedGoogle Scholar
• Churg A, Müller NL, Silva CI, et al. Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias. Am J Surg Pathol. 2007 Feb;31(2):277–284.
   PubMed Web of Science ®Google Scholar
• Hubbard R, Venn A, Lewis S, et al. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med. 2000 Jan;161(1):5–8.
   PubMed Web of Science ®Google Scholar
• Fulton BG, Ryerson CJ. Managing comorbidities in idiopathic pulmonary fibrosis. Int J Gen Med. 2015 Sep;22(8):309–318.
   Google Scholar
• Tomassetti S, Gurioli C, Ryu JH, et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest. 2015 Jan;147(1):157–164.
   PubMed Web of Science ®Google Scholar
• Meyer KC, Decker C, Baughman R. Toxicity and monitoring of immunosuppressive therapy used in systemic autoimmune diseases. Clin Chest Med. 2010 Sep;31(3):565–588.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Meyer KC, Nathanson I, et al. Executive summary: monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Nov;142(5):1284–1288.
   PubMed Web of Science ®Google Scholar
• Meyer KC, Bierach J. Immunosuppressive therapy for autoimmune lung diseases. Immunol Allergy Clin North Am. 2012 Nov;32(4):633–669.
   PubMed Web of Science ®Google Scholar
• Meyer K. Management of interstitial lung disease in elderly patients. Curr Opin Pulm Med. 2012;18:483–492.
   PubMed Web of Science ®Google Scholar